Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion type Assertion NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_head.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion description "[The methodologies proposed in this paper are applied to four gene expression data sets with multiple classes: (a) a hereditary breast cancer data set with (1) BRCA1-mutation, (2) BRCA2-mutation and (3) sporadic breast cancer samples, (b) an acute leukemia data set with (1) acute myeloid leukemia (AML), (2) T-cell acute lymphoblastic leukemia (T-ALL) and (3) B-cell acute lymphoblastic leukemia (B-ALL) samples, (c) a lymphoma data set with (1) diffuse large B-cell lymphoma (DLBCL), (2) B-cell chronic lymphocytic leukemia (BCLL) and (3) follicular lymphoma (FL) samples, and (d) the NCI60 data set with cell lines derived from cancers of various sites of origin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_provenance.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion evidence source_evidence_literature NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_provenance.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion SIO_000772 12217913 NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_provenance.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion wasDerivedFrom befree-2016 NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_provenance.
- NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_assertion wasGeneratedBy ECO_0000203 NP367273.RAnC34CrqrcOh2zzliHe3my5BjlxvXPAApSC3pJsXV-_w130_provenance.